Asian Pacific Journal of Allergy and Immunology

  • HOME
  • ABOUT
  • EDITORS
  • SUBMISSION
    • Online Submission
    • Author Instructions
  • ISSUE
    • Current
    • Early Online
    • Archives
  • PERMISSIONS
  • CONTACT
  • ADVERTISE
Home
 / 
Original Article
 / 
Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation

July 31, 2019
Original Article

Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation

Siriporn Wongwaree,1 Tassalapa Daengsuwan1

1 Division of Allergy and Immunology, Department of Pediatrics, Queen Sirikit National Institute of Child Health, Bangkok, Thailand

Abstract

Background: In Thailand, nebulized ipratropium bromide/fenoterol, is commonly used in addition to salbutamol for severe asthma exacerbation. Recently, nebulized MgSO4 is indicated in GINA 2015 as an additive treatment for severe
cases. However, there is limited data showed the efficacy of both drugs in childhood severe asthma. The purpose of this study to compare efficacy and safety of nebulized MgSO4 and ipratropium bromide/fenoterol in moderate to severe asthma attacks.
Methods: In this a prospective, double-blind, randomized, controlled trial study, we enrolled thirty-three children, age ranged from 2 to 15 years old, with PRAM score ≥ 4 (moderate to severe asthma exacerbation) despite 3 doses of nebulized salbutamol. Each patient was randomized to receive either three doses of nebulized MgSO4 or nebulized ipratropium bromide/fenoterol every 30 minutes. The PRAM score was measured at 0, 30, 60, 90, 120 and 240 minutes after the treatment. The adverse event and admission days were also evaluated.
Results: Sixteen patients received nebulized MgSO4 and seventeen received nebulized ipratropium bromide/fenoterol. Almost patients were classified as having moderate asthmatic attack. There were no statistically significant difference between the two study groups in almost baseline characteristic, PRAM score at 0, 30, 60, 90, 120, 240 minutes. The hospital length of stay was also similar between two groups (p = 0.83). There were no serious events in both groups.
Conclusions: Our double blind, randomized, controlled pilot study demonstrated non-inferior outcomes including clinical benefit and safety of nebulized MgSO4 and nebulized ipratropium bromide/fenoterol among Thai children with acute moderate asthmatic attack.
Key words: asthma, acute asthmatic attack, severe acute asthma, nebulized magnesium sulfate, nebulized ipratropium bromide/fenoterol, isotonic magnesium sulfate,

Full Text
Vol. 40, No. 1
acute asthmatic attack, Asthma, isotonic magnesium sulfate, nebulized ipratropium bromide/fenoterol, nebulized magnesium sulfate, severe acute asthma

Categories

  • Announcement (1)
  • Case Report (23)
  • Early Online (93)
  • Original Article (223)
  • Review Article (29)

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D
Asian Pacific Journal of Allergy and Immunology

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org

Asian Pacific Journal of Allergy and Immunology © 2025 All rights reserved.
All rights reserved | Privacy Policy